一项评估瑞卡帕尼单药一线维持治疗新诊断卵巢癌患者的随机III期试验(ATHENA-MONO/GOG-3020/ENGOT-ov45)
ATHENA-MONO比较瑞卡帕尼与安慰剂用于新诊断晚期高级别卵巢癌一线含铂化疗缓解后的维持治疗,按4:1随机,主要终点为研究者评估的无进展生存期,在HRD人群和意向治疗人群中均观察到显著获益。
要点
- HRD人群:瑞卡帕尼组中位无进展生存期28.7个月 vs 安慰剂组11.3个月(HR 0.47,95%CI 0.31-0.72,P=0.0004)。
- 意向治疗人群:中位无进展生存期20.2个月 vs 9.2个月(HR 0.52,95%CI 0.40-0.68,P<0.0001)。
- HRD阴性人群:中位无进展生存期12.1个月 vs 9.1个月(HR 0.65,95%CI 0.45-0.95)。
核心结论
- 瑞卡帕尼单药作为一线维持治疗有效,在伴和不伴HRD的晚期卵巢癌患者中较安慰剂均带来显著获益。
研究设计与样本
- 随机、双盲、III期试验ATHENA-MONO,入组接受手术减瘤(允许R0/完全切除)且一线铂类双药化疗缓解的III-IV期高级别卵巢癌患者,按4:1随机分配至口服瑞卡帕尼600 mg每日两次或安慰剂。
- 分层因素为HRD检测状态、化疗后残留病灶和手术时机。
- 主要终点为研究者评估的无进展生存期,采用逐步检验程序,先在HRD人群(BRCA突变或BRCA野生型/杂合性缺失高肿瘤)中评估,再在意向治疗人群中评估。
- 截至2022年3月23日数据截止,瑞卡帕尼组427例、安慰剂组111例(HRD人群分别为185例和49例)。
主要发现
- HRD人群:瑞卡帕尼组中位无进展生存期28.7个月(95%CI 23.0至未达到)vs 安慰剂组11.3个月(95%CI 9.1-22.1),log-rank P=0.0004,HR 0.47(95%CI 0.31-0.72)。
- 意向治疗人群:瑞卡帕尼组中位无进展生存期20.2个月(95%CI 15.2-24.7)vs 安慰剂组9.2个月(95%CI 8.3-12.2),log-rank P<0.0001,HR 0.52(95%CI 0.40-0.68)。
- HRD阴性人群:瑞卡帕尼组中位无进展生存期12.1个月(95%CI 11.1-17.7)vs 安慰剂组9.1个月(95%CI 4.0-12.2),HR 0.65(95%CI 0.45-0.95)。
- 最常见的≥3级治疗中出现的不良事件为贫血(瑞卡帕尼组28.7% vs 安慰剂组0%)和中性粒细胞减少(14.6% vs 0.9%)。
临床怎么用
- 原文结论为瑞卡帕尼单药作为一线维持治疗有效,在伴和不伴HRD的晚期卵巢癌患者中较安慰剂均带来显著获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo. METHODS: Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population. RESULTS: As of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 v 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank P = .0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank P < .0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade ≥ 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% v placebo, 0%) and neutropenia (14.6% v 0.9%). CONCLUSION: Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.
引用
- Monk BJ, Parkinson C, Lim MC, et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022. PMID: 35658487. doi:10.1200/JCO.22.01003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。